

## Kyowa Hakko Kirin Announces Changes in Global Management Structure

**Tokyo, Japan, February 5, 2019** ---Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and COO: Masashi Miyamoto, Kyowa Hakko Kirin) announces changes to its global management structure effective April 1, 2019.

“Our business is expanding globally and, in response to this, we have decided to change our global management structure to “One Kyowa Kirin” in anticipation of achieving our vision of making the leap to become a global specialty pharmaceutical company that we are proud of and that is capable of further growth,” said Masashi Miyamoto Ph.D., Executive Director of the Board, President and COO of Kyowa Hakko Kirin. “Under this new structure, Kyowa Kirin Group will be organized both by region\* and function. I am confident that this new structure will further enable us to bring innovative and valuable medicines to the patients all over the world.”

\*Japan, EMEA, North America (US/CAN) and Asia/Pacific

**Effective Date:** April 1, 2019

### Outline of the changes:

#### 1. Reorganization of the US and European organizations

Kyowa Kirin USA Holdings Inc. will be responsible for North America’s (US and Canada) market.

New appointment of President of Kyowa Kirin USA Holdings Inc.: Thomas Stratford Ph.D. (Currently President of Kyowa Kirin International PLC)

Kyowa Kirin International PLC will, in future, be responsible for the EMEA (Europe, Middle East and Africa) market.

New appointment of President of Kyowa Kirin International PLC: Abdul Mullick Ph.D. (Currently Vice President of Kyowa Kirin International PLC)

#### 2. Establishment of a Global Product Management Office

A Global Product Management Office will be newly established directly under the control of president of Kyowa Hakko Kirin to unify the management of Kyowa

Kirin Group's global strategic products (Burosumab, Mogamulizumab, Istradefylline).

New appointment of Head of Global Product Management Office: Tomohiro Sudo  
(Currently Vice President of Kyowa Kirin International PLC)

**Reasons for the changes:**

To maximize the value of Kyowa Hakko Kirin's global strategic products and to further strengthen global governance.

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.